Status and phase
Conditions
Treatments
About
To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC
Full description
In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of pemetrexed. So we design the trial to investigate curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
1.Histological or cytological diagnosis of small-cll lung cancer histology
2.18 years or older
3.Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2
4.Local stage SCLC without distant metastases
5.After 1st-line chemotherapy (EP or IP) at least 4 cycles
6.After radical radiotherapy for primary tumor and lymph node drainage area:including concurrent or sequence chemoradiotherapy
7.CR or PR assessment by RECIST(1.0) before randomized
8.Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x 10^9/L
9.Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases
10.Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
178 participants in 2 patient groups
Loading...
Central trial contact
Fengnan Wang, MD; Hailing Yang, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal